Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

NCT01316692 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Recurrent Melanoma
Stage IIIc Melanoma
Stage IV Melanoma

Interventions

OTHER: laboratory biomarker identification and analysis
PROCEDURE: biopsy
OTHER: immunohistochemistry/tissue microarrays
GENETIC: TdT-mediated dUTP nick end labeling assay
OTHER: mass spectrometry

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]